Bulletin from the Annual General Meeting of SynAct Pharma AB

SynAct Pharma AB (publ) (“SynAct Pharma”) held an Annual General Meeting today, the 15th May 2018. The following is a summary of the decisions taken. All decisions were taken with the required majority.

Adoption of income statement and balance sheet

The Annual General Meeting resolved to adopt the presented income statement and balance sheet, as well as the consolidated income statement and consolidated balance sheet for the financial year 2017.

Distribution of earnings

The Annual General Meeting resolved to distribute the company’s profits according to the proposal made by the Board of Directors in the annual report. The Annual General Meeting also decided that no dividend will be paid for the financial year 2017.

Discharge

The Annual General Meeting resolved to discharge the Board of Directors and the Chief Executive Officer of their liability for the financial year 2017.

Determination of the number of members of the Board of Directors, deputy members and the number of auditors and deputy auditors, and the determination of remuneration to the Board of Directors and auditors

The Annual General Meeting decided that the Board of Directors consist of four members of the Board of Directors and no deputy board member and that board remuneration should be SEK 70,000 to the Chairman of the Board and SEK 60,000 to other members of the Board of Directors, excluding Thomas Jonassen. In addition, the Annual General Meeting decided that an auditor and no deputy auditor should be appointed and that fees for the auditor should be paid according to the approved account in accordance with customary billing standards.

Election of Board of Directors and auditor

The Annual General Meeting re-elected Lars Adlersson, Torbjørn Bjerke, Charlotte Edenius and Thomas Jonassen as members of the Board of Directors. Torbjørn Bjerke was re-elected Chairman of the Board. Furthermore, the Annual General Meeting decided that the company’s auditor MAZARS SET Revisionsbyrå AB be re-elected until the end of the Annual General Meeting held next financial year.

Other

The Annual General Meeting authorised the Board, or the Board’s appointee, to make any minor adjustments to the Annual General Meeting’s decisions that may prove necessary in the registration of decisions.

Lund, May 2018

SynAct Pharma AB (publ)

BOARD OF DIRECTORS

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                                         Henrik Stage

CEO, SynAct Pharma AB                                                                   CFO, SynAct Pharma AB

Telephone: +45 28 44 75 67                                                            Telephone: +45 40 26 09 00
E-mail: joo@synactpharma.com                                                     E-mail: hs@synactpharma.com